


To access current national guidance follow link:

How to process **IVIG** for a new patient?





specialities will be made directly by clinicians (usually the consultant involved in the care of the patient).

Applications for other specialities will be made through the supporting structure of the clinical pharmacy support service to the ward area affected and /or speciality. Please use the <u>adapted</u> UHB SRIAP application form to support completion. <u>IG Database – igd (mdsas.com)</u>



WRH and AH

 Stock should only be taken after approval by the on-call pharmacist (OCP)
Details of the patient, condition being treated for and that supply may be made without SRIAP prior approval to be given to the OCP and recorded appropriately in the EDC record
On-call pharmacist to inform the appropriate clinical pharmacy team lead to ensure that that the retrospective SRIAP application is completed

· EDC stocks will be replenished by pharmacy on the following working day - should stock

Role of the SRIAP

All Provider Trusts that use human normal immunoglobulin (IVIG) are required to participate in a hub and spoke model where approval is required for all IVIG use by the Sub Regional Immunoglobulin Advisory Panel (SRIAP). The local panel for Worcestershire Acute Hospitals Trust is the West Midlands South/Central SRIAP hosted by University Hospitals Birmingham NHS Trust (UHB). The SRIAP has responsibility for managing individual patient access to IVIG including review of eligibility, indications, dose